

Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Growth 2026-2032

<https://marketpublishers.com/r/G31EFFDD6998EN.html>

Date: April 2026

Pages: 127

Price: US\$ 3,660.00 (Single User License)

ID: G31EFFDD6998EN

Abstracts

The global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Swine Hyopneumoniae Mycoplasma Vaccine contains inactivated Mycoplasma hyopneumoniae, which is a light yellow spongy loose mass, which is easy to separate from the bottle wall and quickly dissolves into a uniform suspension after adding diluent. For the prevention of swine mycoplasma pneumonia.

United States market for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Swine Hyopneumoniae Mycoplasma Inactivated Vaccine players cover Zoetis Animal Health, Boehringer-Ingelheim, Eurovet, Hipra, Merck Animal Health, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Industry Forecast" looks at past sales and reviews total world Swine Hyopneumoniae Mycoplasma Inactivated Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Swine Hyopneumoniae Mycoplasma Inactivated Vaccine sales for 2026 through 2032. With Swine Hyopneumoniae Mycoplasma Inactivated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Swine Hyopneumoniae Mycoplasma Inactivated Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Hyopneumoniae Mycoplasma Inactivated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Nasal Spray

Chest Injection

Intramuscular Injection

Intrapulmonary Injection

Segmentation by Application:

Piglets

Adults Pigs

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Zoetis Animal Health

Boehringer-Ingelheim

Eurovet

Hipra

Merck Animal Health

Ceva Animal Health

Intervet (AKZO-NOBEL)

SPAH

Nanjing Tianbang Biological Technology

Sichuan Huapai Bio-pharmaceutical

Guangdong Winsun Bio Pharmaceutical

Sichuan Yihe Animal Medicine

Pulike

Harbin Pharmaceutical Group Bio-Vaccine

Ringpu

JiLin ZhengYe Biological Products

China Animal Husbandry Industry

Key Questions Addressed in this Report

What is the 10-year outlook for the global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market?

What factors are driving Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Swine Hyopneumoniae Mycoplasma Inactivated Vaccine market opportunities vary by end market size?

How does Swine Hyopneumoniae Mycoplasma Inactivated Vaccine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Country/Region, 2021, 2025 & 2032

2.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Segment by Type

2.2.1 Nasal Spray

2.2.2 Chest Injection

2.2.3 Intramuscular Injection

2.2.4 Intrapulmonary Injection

2.2.5 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type

2.2.5.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2021-2026)

2.2.5.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue and Market Share by Type (2021-2026)

2.2.5.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Type (2021-2026)

2.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Segment by Application

2.3.1 Piglets

2.3.2 Adults Pigs

2.3.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application

2.3.3.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Market

Share by Application (2021-2026)

2.3.3.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue and Market Share by Application (2021-2026)

2.3.3.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Breakdown Data by Company

3.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales by Company (2021-2026)

3.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Company (2021-2026)

3.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue by Company (2021-2026)

3.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Company (2021-2026)

3.2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Company (2021-2026)

3.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Company

3.4 Key Manufacturers Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Location Distribution

3.4.2 Players Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SWINE HYOPNEUMONIAE MYCOPLASMA INACTIVATED VACCINE BY GEOGRAPHIC REGION

4.1 World Historic Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Geographic Region (2021-2026)

4.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Country/Region (2021-2026)

4.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales by Country/Region (2021-2026)

4.2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue by Country/Region (2021-2026)

4.3 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth

4.4 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth

4.5 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth

4.6 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth

5 AMERICAS

5.1 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country

5.1.1 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2021-2026)

5.1.2 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2021-2026)

5.2 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026)

5.3 Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region

6.1.1 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2021-2026)

6.1.2 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by

Region (2021-2026)

6.2 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026)

6.3 APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Country

7.1.1 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2021-2026)

7.1.2 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2021-2026)

7.2 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026)

7.3 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Country

8.1.1 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2021-2026)

8.1.2 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2021-2026)

8.2 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales

by Type (2021-2026)

8.3 Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales
by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Swine Hyopneumoniae Mycoplasma
Inactivated Vaccine

10.3 Manufacturing Process Analysis of Swine Hyopneumoniae Mycoplasma
Inactivated Vaccine

10.4 Industry Chain Structure of Swine Hyopneumoniae Mycoplasma Inactivated
Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Distributors

11.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Customer

12 WORLD FORECAST REVIEW FOR SWINE HYOPNEUMONIAE MYCOPLASMA INACTIVATED VACCINE BY GEOGRAPHIC REGION

12.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size
Forecast by Region

12.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Forecast by

Region (2027-2032)

12.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Forecast by Type (2027-2032)

12.7 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Zoetis Animal Health

13.1.1 Zoetis Animal Health Company Information

13.1.2 Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.1.3 Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Zoetis Animal Health Main Business Overview

13.1.5 Zoetis Animal Health Latest Developments

13.2 Boehringer-Ingelheim

13.2.1 Boehringer-Ingelheim Company Information

13.2.2 Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.2.3 Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Boehringer-Ingelheim Main Business Overview

13.2.5 Boehringer-Ingelheim Latest Developments

13.3 Eurovet

13.3.1 Eurovet Company Information

13.3.2 Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.3.3 Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Eurovet Main Business Overview

13.3.5 Eurovet Latest Developments

13.4 Hipra

- 13.4.1 Hipra Company Information
- 13.4.2 Hipra Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
- 13.4.3 Hipra Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.4.4 Hipra Main Business Overview
- 13.4.5 Hipra Latest Developments
- 13.5 Merck Animal Health
 - 13.5.1 Merck Animal Health Company Information
 - 13.5.2 Merck Animal Health Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.5.3 Merck Animal Health Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Merck Animal Health Main Business Overview
 - 13.5.5 Merck Animal Health Latest Developments
- 13.6 Ceva Animal Health
 - 13.6.1 Ceva Animal Health Company Information
 - 13.6.2 Ceva Animal Health Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.6.3 Ceva Animal Health Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Ceva Animal Health Main Business Overview
 - 13.6.5 Ceva Animal Health Latest Developments
- 13.7 Intervet (AKZO-NOBEL)
 - 13.7.1 Intervet (AKZO-NOBEL) Company Information
 - 13.7.2 Intervet (AKZO-NOBEL) Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.7.3 Intervet (AKZO-NOBEL) Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Intervet (AKZO-NOBEL) Main Business Overview
 - 13.7.5 Intervet (AKZO-NOBEL) Latest Developments
- 13.8 SPAH
 - 13.8.1 SPAH Company Information
 - 13.8.2 SPAH Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.8.3 SPAH Swine Hypopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 SPAH Main Business Overview
 - 13.8.5 SPAH Latest Developments

13.9 Nanjing Tianbang Biological Technology

13.9.1 Nanjing Tianbang Biological Technology Company Information

13.9.2 Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.9.3 Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Nanjing Tianbang Biological Technology Main Business Overview

13.9.5 Nanjing Tianbang Biological Technology Latest Developments

13.10 Sichuan Huapai Bio-pharmaceutical

13.10.1 Sichuan Huapai Bio-pharmaceutical Company Information

13.10.2 Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.10.3 Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Sichuan Huapai Bio-pharmaceutical Main Business Overview

13.10.5 Sichuan Huapai Bio-pharmaceutical Latest Developments

13.11 Guangdong Winsun Bio Pharmaceutical

13.11.1 Guangdong Winsun Bio Pharmaceutical Company Information

13.11.2 Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.11.3 Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Guangdong Winsun Bio Pharmaceutical Main Business Overview

13.11.5 Guangdong Winsun Bio Pharmaceutical Latest Developments

13.12 Sichuan Yihe Animal Medicine

13.12.1 Sichuan Yihe Animal Medicine Company Information

13.12.2 Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.12.3 Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Sichuan Yihe Animal Medicine Main Business Overview

13.12.5 Sichuan Yihe Animal Medicine Latest Developments

13.13 Pulike

13.13.1 Pulike Company Information

13.13.2 Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

13.13.3 Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Pulike Main Business Overview

- 13.13.5 Pulike Latest Developments
- 13.14 Harbin Pharmaceutical Group Bio-Vaccine
 - 13.14.1 Harbin Pharmaceutical Group Bio-Vaccine Company Information
 - 13.14.2 Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.14.3 Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 Harbin Pharmaceutical Group Bio-Vaccine Main Business Overview
 - 13.14.5 Harbin Pharmaceutical Group Bio-Vaccine Latest Developments
- 13.15 Ringpu
 - 13.15.1 Ringpu Company Information
 - 13.15.2 Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.15.3 Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.15.4 Ringpu Main Business Overview
 - 13.15.5 Ringpu Latest Developments
- 13.16 JiLin ZhengYe Biological Products
 - 13.16.1 JiLin ZhengYe Biological Products Company Information
 - 13.16.2 JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.16.3 JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.16.4 JiLin ZhengYe Biological Products Main Business Overview
 - 13.16.5 JiLin ZhengYe Biological Products Latest Developments
- 13.17 China Animal Husbandry Industry
 - 13.17.1 China Animal Husbandry Industry Company Information
 - 13.17.2 China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
 - 13.17.3 China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.17.4 China Animal Husbandry Industry Main Business Overview
 - 13.17.5 China Animal Husbandry Industry Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Nasal Spray
- Table 4. Major Players of Chest Injection
- Table 5. Major Players of Intramuscular Injection
- Table 6. Major Players of Intrapulmonary Injection
- Table 7. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026) & (K Doses)
- Table 8. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2021-2026)
- Table 9. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Type (2021-2026) & (\$ million)
- Table 10. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Type (2021-2026)
- Table 11. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Type (2021-2026) & (US\$/Dose)
- Table 12. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale by Application (2021-2026) & (K Doses)
- Table 13. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Market Share by Application (2021-2026)
- Table 14. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Application (2021-2026) & (\$ million)
- Table 15. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Application (2021-2026)
- Table 16. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Application (2021-2026) & (US\$/Dose)
- Table 17. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Company (2021-2026) & (K Doses)
- Table 18. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Company (2021-2026)
- Table 19. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Company (2021-2026) & (\$ millions)
- Table 20. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue

Market Share by Company (2021-2026)

Table 21. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Price by Company (2021-2026) & (US\$/Dose)

Table 22. Key Manufacturers Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Producing Area Distribution and Sales Area

Table 23. Players Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Products Offered

Table 24. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Geographic Region (2021-2026) & (K Doses)

Table 28. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share Geographic Region (2021-2026)

Table 29. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 30. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Geographic Region (2021-2026)

Table 31. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country/Region (2021-2026) & (K Doses)

Table 32. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country/Region (2021-2026)

Table 33. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country/Region (2021-2026) & (\$ millions)

Table 34. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country/Region (2021-2026)

Table 35. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2021-2026) & (K Doses)

Table 36. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2021-2026)

Table 37. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 38. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026) & (K Doses)

Table 39. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2021-2026) & (K Doses)

Table 40. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2021-2026) & (K Doses)

Table 41. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Region (2021-2026)

Table 42. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region (2021-2026) & (\$ millions)

Table 43. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026) & (K Doses)

Table 44. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2021-2026) & (K Doses)

Table 45. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2021-2026) & (K Doses)

Table 46. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 47. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026) & (K Doses)

Table 48. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2021-2026) & (K Doses)

Table 49. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2021-2026) & (K Doses)

Table 50. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2021-2026)

Table 51. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2021-2026) & (K Doses)

Table 52. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2021-2026) & (K Doses)

Table 53. Key Market Drivers & Growth Opportunities of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine

Table 54. Key Market Challenges & Risks of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine

Table 55. Key Industry Trends of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine

Table 56. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Distributors List

Table 59. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Customer List

Table 60. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Region (2027-2032) & (K Doses)

Table 61. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 62. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales

Forecast by Country (2027-2032) & (K Doses)

Table 63. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 64. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Region (2027-2032) & (K Doses)

Table 65. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 66. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Country (2027-2032) & (K Doses)

Table 67. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Country (2027-2032) & (K Doses)

Table 69. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 70. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Type (2027-2032) & (K Doses)

Table 71. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 72. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Forecast by Application (2027-2032) & (K Doses)

Table 73. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 74. Zoetis Animal Health Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 75. Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 76. Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 77. Zoetis Animal Health Main Business

Table 78. Zoetis Animal Health Latest Developments

Table 79. Boehringer-Ingelheim Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 80. Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 81. Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 82. Boehringer-Ingelheim Main Business

Table 83. Boehringer-Ingelheim Latest Developments

Table 84. Eurovet Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 85. Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 86. Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 87. Eurovet Main Business

Table 88. Eurovet Latest Developments

Table 89. Hipra Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 90. Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 91. Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 92. Hipra Main Business

Table 93. Hipra Latest Developments

Table 94. Merck Animal Health Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 95. Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 96. Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 97. Merck Animal Health Main Business

Table 98. Merck Animal Health Latest Developments

Table 99. Ceva Animal Health Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 100. Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 101. Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 102. Ceva Animal Health Main Business

Table 103. Ceva Animal Health Latest Developments

Table 104. Intervet (AKZO-NOBEL) Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 105. Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated

Vaccine Product Portfolios and Specifications

Table 106. Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 107. Intervet (AKZO-NOBEL) Main Business

Table 108. Intervet (AKZO-NOBEL) Latest Developments

Table 109. SPAH Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 110. SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 111. SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 112. SPAH Main Business

Table 113. SPAH Latest Developments

Table 114. Nanjing Tianbang Biological Technology Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 115. Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 116. Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 117. Nanjing Tianbang Biological Technology Main Business

Table 118. Nanjing Tianbang Biological Technology Latest Developments

Table 119. Sichuan Huapai Bio-pharmaceutical Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 120. Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 121. Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 122. Sichuan Huapai Bio-pharmaceutical Main Business

Table 123. Sichuan Huapai Bio-pharmaceutical Latest Developments

Table 124. Guangdong Winsun Bio Pharmaceutical Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 125. Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 126. Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 127. Guangdong Winsun Bio Pharmaceutical Main Business
Table 128. Guangdong Winsun Bio Pharmaceutical Latest Developments
Table 129. Sichuan Yihe Animal Medicine Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 131. Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 132. Sichuan Yihe Animal Medicine Main Business
Table 133. Sichuan Yihe Animal Medicine Latest Developments
Table 134. Pulike Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 136. Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 137. Pulike Main Business
Table 138. Pulike Latest Developments
Table 139. Harbin Pharmaceutical Group Bio-Vaccine Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 141. Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 142. Harbin Pharmaceutical Group Bio-Vaccine Main Business
Table 143. Harbin Pharmaceutical Group Bio-Vaccine Latest Developments
Table 144. Ringpu Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications
Table 146. Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 147. Ringpu Main Business

Table 148. Ringpu Latest Developments

Table 149. JiLin ZhengYe Biological Products Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 150. JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 151. JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 152. JiLin ZhengYe Biological Products Main Business

Table 153. JiLin ZhengYe Biological Products Latest Developments

Table 154. China Animal Husbandry Industry Basic Information, Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 155. China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolios and Specifications

Table 156. China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 157. China Animal Husbandry Industry Main Business

Table 158. China Animal Husbandry Industry Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
- Figure 2. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Growth Rate 2021-2032 (K Doses)
- Figure 7. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country/Region (2025)
- Figure 10. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Nasal Spray
- Figure 12. Product Picture of Chest Injection
- Figure 13. Product Picture of Intramuscular Injection
- Figure 14. Product Picture of Intrapulmonary Injection
- Figure 15. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type in 2026
- Figure 16. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Type (2021-2026)
- Figure 17. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Consumed in Piglets
- Figure 18. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market: Piglets (2021-2026) & (K Doses)
- Figure 19. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Consumed in Adults Pigs
- Figure 20. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market: Adults Pigs (2021-2026) & (K Doses)
- Figure 21. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sale Market Share by Application (2025)
- Figure 22. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue

Market Share by Application in 2026

Figure 23. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Company in 2026 (K Doses)

Figure 24. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Company in 2026

Figure 25. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Company in 2026 (\$ millions)

Figure 26. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Company in 2026

Figure 27. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Geographic Region (2021-2026)

Figure 28. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Geographic Region in 2026

Figure 29. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2021-2026 (K Doses)

Figure 30. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2021-2026 (\$ millions)

Figure 31. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2021-2026 (K Doses)

Figure 32. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2021-2026 (\$ millions)

Figure 33. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2021-2026 (K Doses)

Figure 34. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2021-2026 (\$ millions)

Figure 35. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2021-2026 (K Doses)

Figure 36. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2021-2026 (\$ millions)

Figure 37. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country in 2026

Figure 38. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2021-2026)

Figure 39. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2021-2026)

Figure 40. Americas Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2021-2026)

Figure 41. United States Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 42. Canada Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 43. Mexico Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 44. Brazil Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 45. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Region in 2026

Figure 46. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Region (2021-2026)

Figure 47. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2021-2026)

Figure 48. APAC Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2021-2026)

Figure 49. China Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 50. Japan Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 51. South Korea Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 52. Southeast Asia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 53. India Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 54. Australia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 55. China Taiwan Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 56. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country in 2026

Figure 57. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2021-2026)

Figure 58. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2021-2026)

Figure 59. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2021-2026)

Figure 60. Germany Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 61. France Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue

Growth 2021-2026 (\$ millions)

Figure 62. UK Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue

Growth 2021-2026 (\$ millions)

Figure 63. Italy Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue

Growth 2021-2026 (\$ millions)

Figure 64. Russia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue

Growth 2021-2026 (\$ millions)

Figure 65. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2021-2026)

Figure 66. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2021-2026)

Figure 67. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2021-2026)

Figure 68. Egypt Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 69. South Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 70. Israel Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 71. Turkey Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 72. GCC Countries Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine in 2026

Figure 74. Manufacturing Process Analysis of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine

Figure 75. Industry Chain Structure of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine

Figure 76. Channels of Distribution

Figure 77. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Forecast by Region (2027-2032)

Figure 78. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share Forecast by Region (2027-2032)

Figure 79. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share Forecast by Type (2027-2032)

Figure 80. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share Forecast by Type (2027-2032)

Figure 81. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales

Market Share Forecast by Application (2027-2032)

Figure 82. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue

Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G31EFFDD6998EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G31EFFDD6998EN.html>